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Background
Resveratrol (RSV) is a polyphenolic phytoalexin (3, 5, 4’-
trihydroxystilbene) produced by plants as a protective
defense mechanism against pathogens or environmental
stress [1]. RSV is found in various plant species such as
peanuts, mulberries, Japanese knotweed and skin of
grapes. As such RSV is a component of red wine. Interest-
ingly, the prevalence of coronary heart disease (CHD) is
comparatively reduced in people from Southern France
despite high dietary intake of saturated fats [1-3]. In order
to uncork this “French-Paradox”, as well as to identify
other potential health benefits of RSV in relation to can-
cer, infection and inflammation, we studied molecular
docking of RSV with known protein structures implicated
in health and disease and further dissected the potential
molecular networks regulated by RSV.
Materials and methods
TarFishDock Server (http://www.dddc.ac.cn/tarfisdock)
was used to dock RSV with 698 known drug target pro-
teins in the Potential Drug Target Database (PDTB). This
automated webserver enables docking of small molecules
with a broad range of Protein Structures available in the
Protein Drug Target Database (PDTD) (http://www.dddc.
ac.cn/pdtd/) [4]. Furthermore, to define biological networks
and dissect the functional relationship among the genes
regulated by RSV, we performed pathway analyses using
the Ingenuity Pathways Analysis (IPA) (Ingenuity Systems,
Redwood City, CA, USA). The significance of the associa-
tion of RSV with gene networks was calculated by ratio
and/or Fisher’s exact.
Results
RSV docking with known protein structures has uncov-
ered its potential to bind with proteins (Table 1) such as
Matrix Metalloproteinase-8 (MMP8), Nicotinate-nucleo-
tide Adenylyltransferase, Myeloperoxidase (MPO),
Oxidosqualene cyclase, Nitric Oxide Synthase (NOS) etc.,.
These proteins are commonly implicated in cancer, cardi-
ovascular diseases, multiple sclerosis, infection, inflamma-
tion, sepsis and diabetic retinopathy. Additionally, the IPA
analyses have revealed that a total of 350 genes were either
associated or regulated by RSV in health and disease.
Conclusions
Our study has identified potential molecular networks
regulated by RSV in cancer, cardiovascular diseases, infec-
tion, inflammation and neurodegenerative disorders. RSV
is reported to cause vasorelaxation and improve myocar-
dial function by increasing endothelial nitric oxide
synthase, and thereby substantially uncork the “French
Paradox”. Besides, the present study offers a method to
deduce the suitability of small molecules such as RSV for
clinical trials for specific disease pathology. Conversely,
precise docking with “Druggable” target proteins identified
in our current study would certainly be essential to obtain
comprehensive information to design RSV analogues for
the treatment of an array of diseases afflicting humans in
the near future.
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